Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases and other eye conditions. The company uses its proprietary bioresorbable hydrogel-based formulation technology to create sustained-release drug delivery systems. Its marketed product, DEXTENZA, is a dexamethasone ophthalmic insert used to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. The company's pipeline includes AXPAXLI, an axitinib intravitreal hydrogel in phase 3 trials for wet age-related macular degeneration and non-proliferative diabetic retinopathy, and OTX-TIC, a travoprost intracameral hydrogel that has completed phase 2 trials for open-angle glaucoma or ocular hypertension.

Ocular Therapeutix is listed on the Nasdaq Global Market under the ticker symbol OCUL. Its shares are traded in US dollars (USD). The company is headquartered in Bedford, Massachusetts, and operates primarily in the United States.

Ocular Therapeutix operates in the Healthcare sector and specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing innovative therapies for eye conditions, leveraging its hydrogel-based drug delivery platform to address unmet medical needs in ophthalmology.

Ocular Therapeutix is headquartered in Bedford, Massachusetts, United States. The company primarily serves the US market, as indicated by its description summary. It has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, suggesting potential expansion into other regions through partnerships.

Ocular Therapeutix's pipeline includes several key product candidates. AXPAXLI is an axitinib intravitreal hydrogel currently in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy. OTX-TIC is a travoprost intracameral hydrogel that has completed phase 2 clinical trials for open-angle glaucoma or ocular hypertension. The company's marketed product, DEXTENZA, is already approved for post-surgical ocular inflammation and pain, as well as allergic conjunctivitis.